CFO
JAZZ icon

CVA Family Office’s Jazz Pharmaceuticals JAZZ Stock Holding History

CVA Family Office’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.9K Buy
+84
New +$14.7K ﹤0.01% 864
2023
Q2 		– Sell
-5
Closed -$732 – 1041
2023
Q1 		$732 Buy
+5
New +$740 ﹤0.01% 923

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

CVA Family Office's JAZZ Position: Q1 2026 in Review

CVA Family Office opened a new position in Jazz Pharmaceuticals (JAZZ) in Q1 2026: 84 shares worth $15.9K. The stake represents ﹤0.01% of the portfolio and ranks #864 among its holdings. This is a return to the name: CVA Family Office previously reported a position in JAZZ as recently as Q1 2023.

CVA Family Office first reported a position in JAZZ in Q1 2023 and has held it in 2 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • CVA Family Office held 84 shares of Jazz Pharmaceuticals worth $15.9K as of Q1 2026.
  • Jazz Pharmaceuticals was a new CVA Family Office position in Q1 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of CVA Family Office's portfolio in Q1 2026, its #864 holding.
  • CVA Family Office first reported a position in Jazz Pharmaceuticals in Q1 2023 and has held it in 2 quarters since.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on CVA Family Office's 13F filing for Q1 2026, filed 29 Apr 2026.